Sergio Amadori

Active 1982–2025

94
Papers
29,309
Citations
77
h-index
92
i10-index

Citations

Citations per year for Sergio Amadori1948: 1 citations1984: 4 citations1985: 1 citations1986: 1 citations1987: 2 citations1988: 4 citations1989: 2 citations1990: 4 citations1991: 7 citations1992: 6 citations1993: 8 citations1994: 14 citations1995: 21 citations1996: 10 citations1997: 15 citations1998: 17 citations1999: 18 citations2000: 24 citations2001: 32 citations2002: 52 citations2003: 74 citations2004: 65 citations2005: 91 citations2006: 87 citations2007: 129 citations2008: 166 citations2009: 138 citations2010: 181 citations2011: 194 citations2012: 191 citations2013: 193 citations2014: 174 citations2015: 183 citations2016: 195 citations2017: 206 citations2018: 233 citations2019: 982 citations2020: 1,018 citations2021: 958 citations2022: 681 citations2023: 552 citations2024: 731 citations2025: 281 citations2026: 3 citations1949–1983: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,703 citing papers, 25.9% of this breakdownGermany: 882 citing papers, 8.4% of this breakdownChina: 830 citing papers, 7.9% of this breakdownItaly: 771 citing papers, 7.4% of this breakdownUnited Kingdom: 658 citing papers, 6.3% of this breakdownFrance: 603 citing papers, 5.8% of this breakdownNetherlands: 362 citing papers, 3.5% of this breakdownCanada: 349 citing papers, 3.3% of this breakdownSpain: 332 citing papers, 3.2% of this breakdownJapan: 221 citing papers, 2.1% of this breakdownSwitzerland: 214 citing papers, 2.1% of this breakdownAustralia: 210 citing papers, 2% of this breakdown
0%25.9%Other 22.1%

Fields

  • Medicine79.9%
  • Biochemistry, Genetics and Molecular Biology14.7%
  • Immunology and Microbiology3.3%
  • Computer Science0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.2%
  • Agricultural and Biological Sciences0.2%
  • Other1.1%

Topics

  • Acute Myeloid Leukemia Research18.3%
  • Acute Lymphoblastic Leukemia research5.2%
  • Hematopoietic Stem Cell Transplantation4.7%
  • Chronic Myeloid Leukemia Treatments4.2%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment3.4%
  • Retinoids in leukemia and cellular processes3.1%
  • Other61.1%

Coauthors

All papers

Open in search
  1. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 5,868

  2. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 2,198

  3. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Lancet 2023 cited by 366

  4. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2009 cited by 3,392

  5. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hartmut Link, Maria Grazia Kropp, Alessandro Rambaldi, Giorgio La Nasa, Mario Luppi, Fabio Ciceri, Olimpia Finizio, Adriano Venditti, Francesco Fabbiano, Konstanze Döhner, Michaela Sauer, Arnold Ganser, Sergio Amadori, Franco Mandelli, Hartmut Döhner, Gerhard Ehninger, Richard F. Schlenk, Uwe Platzbecker - New England Journal of Medicine 2013 cited by 1,606

  6. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Antonietta Irno-Consalvo, Tiziana Ottone, Serena Lavorgna, Maria Teresa Voso, Francesco Lo‐Coco, William Arcese, Sergio Amadori - Blood 2019 cited by 215

  7. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 348

  8. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sergio Amadori, Insa Gathmann, Axel Benner, Céline Pallaud, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield - Blood 2019 cited by 193

  9. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chiara Frairia, Enrico Maria Pogliani, Claudio Fozza, Alfonso Maria D’Arco, Nicola Di Renzo, Agostino Cortelezzi, Francesco Fabbiano, Konstanze Döhner, Arnold Ganser, Hartmut Döhner, Sergio Amadori, Franco Mandelli, Gerhard Ehninger, Richard F. Schlenk, Francesco Lo‐Coco - Journal of Clinical Oncology 2016 cited by 392

  10. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab

    Authors: , , , , , , - Blood 2008 cited by 406

  11. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study

    Authors: , , , , , , , , , , , , , , , , , , , , - Haematologica 2012 cited by 336

  12. IKZF1 (Ikaros) Deletions in BCR-ABL1 –Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 322

  13. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Donald Small, B. Douglas Smith - Blood 2011 cited by 399

  14. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ulrich Dührsen, Frédéric Baron, Stefan Suciu, Sergio Amadori, Adriano Venditti, Gerwin Huls, Jürgen Finke, Nicolaas Petrus Michael Schaap, Andrius Zucenka, Stephan Metzelder, Edgar Jost, Zinaida Perić, Fabio Forghieri, Bernadino Allione, Maurizio Martelli, Anna Paola Iori, Sebastian Wittnebel, Andrea Mengarelli, Annalisa Imovilli, Attilio Olivieri, Bernard José Marie De Prijck, Marjolein W.M. van der Poel, Christian Junghanß, Helmut Rainer Salih, Agostino Tafuri, José Eduardo Guimarães, Maurizio Musso, Paolo De Fabritiis, Patrice Chevallier, Dominik Luc Selleslag, Nicola Cascavilla, Zwi Berneman, Aurélie Jaspers, Eliana Zuffa, Gaëtan Vanstraelen, Giuseppe Visani, Maria Louisa Henriëtte Cuijpers, Ann De Becker, Anna Maria Mianulli, Björn Hackanson, Georgi Georgiev Mihaylov, Giovanni Martinelli, Stefania Paolini, Pier Luigi Zinzani, Martin Henkes, Haifa Kathrin Al-Ali, Paul La Rosée, Anna Chierichini, Laura Cudillo, Giorgina Specchia, Njetočka Gredelj Šimec, Silvana Franca Capalbo, Giuseppina Spinosa, Stefano Molica, Susan Dorothé de Jonge-Peeters - The Lancet Haematology 2023 cited by 37

  15. Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2005 cited by 647

  16. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hartmut Döhner, Richard M. Stone - Leukemia 2021 cited by 98

  17. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2021 cited by 89

  18. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2022 cited by 39

  19. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3 -Mutated Clones in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2015 cited by 86

  20. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2011 cited by 186

  21. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

    Authors: , , , , , , , , , - Blood 2008 cited by 331

  22. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adriano Venditti, Anne Hagemeijer, Marco Mancini, Joop H. Jansen, Daniela Cilloni, Liv Meert, Paola Fazi, Marco Vignetti, Silvia Maria Trisolini, Franco Mandelli, Théo de Witte - Journal of Clinical Oncology 2013 cited by 168

  23. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow

    Authors: , , , , , , , , , , , , , , , - Haematologica 2007 cited by 90

  24. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John C. Byrd, Christian Thiede, Konstanze Döhner, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield, Francesco Lo‐Coco - Blood Advances 2020 cited by 60